|27.47||-0.1100||-0.40%||Vol 121.43K||1Y Perf -23.54%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-0.32 -1.16%|
|Target Price||42.50||Analyst Rating||Moderate Buy 2.50|
|Potential %||54.71||Finscreener Ranking||★★★★★ 66.75|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 73.94|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 84.43|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||20.86||Earnings Rating||Neutral|
|Market Cap||814.02M||Earnings Date||3rd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.61|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||143.31K|
|Avg. Monthly Volume||195.24K|
|Avg. Quarterly Volume||217.26K|
Fulgent Genetics Inc. (NASDAQ: FLGT) stock closed at 27.58 per share at the end of the most recent trading day (a -0.18% change compared to the prior day closing price) with a volume of 158.33K shares and market capitalization of 814.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 139 people. Fulgent Genetics Inc. CEO is Ming Hsieh.
The one-year performance of Fulgent Genetics Inc. stock is -23.54%, while year-to-date (YTD) performance is -7.39%. FLGT stock has a five-year performance of 676.9%. Its 52-week range is between 23.09 and 44.09, which gives FLGT stock a 52-week price range ratio of 20.86%
Fulgent Genetics Inc. currently has a PE ratio of 3.40, a price-to-book (PB) ratio of 0.70, a price-to-sale (PS) ratio of 1.66, a price to cashflow ratio of 3.10, a PEG ratio of -, a ROA of 22.39%, a ROC of 22.95% and a ROE of 25.20%. The company’s profit margin is 30.11%, its EBITDA margin is 49.20%, and its revenue ttm is $551.26 Million , which makes it $18.24 revenue per share.
Of the last four earnings reports from Fulgent Genetics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Fulgent Genetics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fulgent Genetics Inc. is Moderate Buy (2.5), with a target price of $42.5, which is +54.71% compared to the current price. The earnings rating for Fulgent Genetics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fulgent Genetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fulgent Genetics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.20, ATR14 : 0.80, CCI20 : 68.88, Chaikin Money Flow : -0.08, MACD : 0.43, Money Flow Index : 36.34, ROC : 5.31, RSI : 58.03, STOCH (14,3) : 76.34, STOCH RSI : 0.03, UO : 42.81, Williams %R : -23.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fulgent Genetics Inc. in the last 12-months were: Gao Hanlin (Sold 1 000 shares of value $40 296 ), Hanlin Gao (Sold 2 386 shares of value $85 232 ), Kim Paul (Sold 15 767 shares of value $530 159 ), Paul Kim (Sold 653 shares of value $23 070 ), Xie Jian (Sold 7 169 shares of value $239 759 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.